My Companies
Notification
Account
Log Out
Login
Board approved, subject to shareholder and regulatory approval, acquisition of 92.20% of Archit Life Science via swap, issuing up to 3.72 crore shares at ₹65 each for target shares valued at ₹130 each. Authorised capital will rise from ₹25 crore to ₹60 crore. Context: brings the former subsidiary back into the group.
Archit Organosys Approves 92.2% Archit Life Science Acquisition Via Share Swap
Archit Organosys Schedules Board Meeting To Consider Equity Fund Raise
Archit Organosys Board To Consider Equity Fund Raise On September 3